At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 4 enrolled
Drug / intervention
Vancomycindrug
Likely dose
Vancomycin 20 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Single-site, Open-label, Pharmacokinetic Study of Intermittent Intraperitoneal Vancomycin in Adult Subjects Receiving Automated Peritoneal Dialysis
In Brief
A Phase 1 clinical trial evaluating Vancomycin for Peritoneal Dialysis-associated Peritonitis. Completed, enrolled 4 participants across 1 site.
Detailed Summary
Vancomycin is the most commonly used empiric treatment for infectious peritonitis in patients on peritoneal dialysis. Current dosing and monitoring for safety and efficacy is empiric, especially for those on rapid-cycling modalities. The goal of this study is to understand the pharmacokinetics of vancomycin in patients on rapid-cycling peritoneal dialysis modalities in order to derive an optimal dosing regimen.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartNov 2018
Primary CompletionAug 2020
Study CompletionOct 2020
TodayJul 2026
First PostedSep 26, 2018
Enrollment StartNov 15, 2018
Primary CompletionAug 30, 2020
Study CompletionOct 1, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.8 years ago
Interventions
Vancomycindrug
Vancomycin one-time 20 mg/kg intraperitoneal dose.